Search Results - "Agell, Helena" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

by Simpson, Eric L., de Bruin-Weller, Marjolein, Hong, H. Chih-ho, Staumont-Sallé, Delphine, Blauvelt, Andrew, Eyerich, Kilian, Gooderham, Melinda, Shahriari, Mona, Mallbris, Lotus, Atwater, Amber Reck, Rueda, Maria Jose, Ding, Yuxin, Liu, Zhuqing, Agell, Helena, Silverberg, Jonathan I.
Published in Dermatologic therapy (01.05.2024)

Get full text

Journal Article

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

by Silverberg, Jonathan I., Wollenberg, Andreas, Stein Gold, Linda, Del Rosso, James, Yosipovitch, Gil, Lio, Peter, Carrascosa, Jose-Manuel, Gallo, Gaia, Ding, Yuxin, Xu, Zhenhui, Casillas, Marta, Pierce, Evangeline, Agell, Helena, Ständer, Sonja
Published in Dermatology and therapy (01.08.2024)

Get full text

Journal Article

50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis

50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis

by Gold, Linda Stein, Schuttelaar, Marie Louise, Prajapati, Vimal H., Homey, Bernhard, Strowd, Lindsay, Dossenbach, Martin, Liu, Chunyuan, Zhong, Jinglin, Pierce, Evangeline, Agell, Helena, Silvestre, Juan Francisco
Published in Journal of the American Academy of Dermatology (01.09.2024)

Get full text

Journal Article

708 - Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years

708 - Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years

by Simpson, Eric, Biedermann, Tilo, Kircik, Leon, Chovatiya, Raj, Figueras-Nart, Ignasi, Casillas, Marta, Gallo, Gaia, Ding, Yuxin, Hu, Chaoran, Pierce, Evangeline, Agell, Helena, Vestergaard, Christian
Published in British journal of dermatology (1951) (08.08.2024)

Get full text

Journal Article

42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy

42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy

by Guttman-Yassky, Emma, Rosmarin, David, Thyssen, Jacob, Weidinger, Stephan, Bieber, Thomas, Elmaraghy, Hany, Atwater, Amber Reck, Pierce, Evangeline, Xu, Chenjia, Gimeno, Helena Agell, Simpson, Eric
Published in Journal of the American Academy of Dermatology (01.09.2023)

Get full text

Journal Article

380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52

380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52

by Silverberg, Jonathan I, Wollenberg, Andreas , Gold, Linda Stein, Lio, Peter, Carrascosa, Jose Manuel , Gallo, Gaia, Casillas, Marta , Ding, Yuxin, Chen, Sherry, Agell, Helena , Thyssen, Jacob P
Published in British journal of dermatology (1951) (20.06.2023)

Get full text

Journal Article

619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

by Warren, Richard B, de Bruin-Weller, Marjolein, Tsianakas, Athanasios, Khemis, Abdallah, Szepietowski, Jacek C, Chih-Ho Hong, H, Armengol, Clara, Falqués, Meritxell, Agell, Helena, Massana, Eric, Gil, Esther Garcia, Weidinger, Stephan
Published in British journal of dermatology (1951) (08.08.2024)

Get full text

Journal Article

626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age

626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age

by Armstrong, April, Zirwas, Matthew, Napolitano, Maddalena, Torres, Tiago, Staumont-Salle, Delphine, Atwater, Amber Reck, Dossenbach, Martin, Agell, Helena, Chen, Sherry, Qiao, Meihua, Pierce, Evangeline, Piruzeli, Maria Lucia Buziqui, Mostaghimi, Arash
Published in British journal of dermatology (1951) (08.08.2024)

Get full text

Journal Article

400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy

400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy

by Guttman-Yassky, Emma, Rosmarin, David, Thyssen, Jacob P, Weidinger, Stephan, Bieber, Thomas , Elmaraghy, Hany, Atwater, Amber Reck , Pierce, Evangeline, Xu, Chenjia , Gimeno, Helena Agell, Simpson, Eric, Mourey, Robert J
Published in British journal of dermatology (1951) (20.06.2023)

Get full text

Journal Article

Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)

Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)

by Simpson, Eric, Fernández-Peñas, Pablo, de Bruin-Weller, Marjolein, Lio, Peter A, Chu, Chia-Yu, Ezzedine, Khaled, Agell, Helena, Casillas, Marta, Ding, Yuxin, Yang, Fan Emily, Pierce, Evangeline, Bieber, Thomas
Published in Advances in therapy (09.09.2024)

Get full text

Journal Article

Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

by Silverberg, Jonathan, Kircik, Leon, Gooderham, Melinda, Gallo, Gaia, Wolf, Eric, Agell, Helena, Yang, Fan Emily, Ding, Yuxin, Simpson, Eric
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

by Silverberg, Jonathan I., Wollenberg, Andreas, Stein Gold, Linda, Del Rosso, James, Yosipovitch, Gil, Lio, Peter, Carrascosa, Jose-Manuel, Gallo, Gaia, Ding, Yuxin, Xu, Zhenhui, Casillas, Marta, Pierce, Evangeline, Agell, Helena, Ständer, Sonja
Published in Dermatology and therapy (01.11.2024)

Get full text

Journal Article

Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year

Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year

by Yosipovitch, Gil, Zeidler, Claudia, Apfelbacher, Christian J., Laquer, Vivian, Kim, Brian S., Casillas, Marta, Pierce, Evangeline, Chen, Sherry, Qiao, Meihua, Agell, Helena, Del Rosso, James
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article

Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

by Simpson, Eric, Yosipovitch, Gil, Eyerich, Kilian, Staumont-Sallé, Delphine, Shahriari, Mona, Gallo, Gaia, Wolf, Eric, Pierce, Evangeline, Liu, Chunyuan, Zhong, Jinglin, Agell, Helena, De Bruin-Weller, Marjolein
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article

Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis

Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis

by Del Rosso, James, Yosipovitch, Gil, Ständer, Sonja, Silverberg, Jonathan, Wollenberg, Andreas, Lio, Peter A., Carrascosa, Jose Manuel, Gallo, Gaia, Casillas, Marta, Pierce, Evangeline, Ding, Yuxin, Xu, Zhenhui, Agell, Helena, Stein Gold, Linda
Published in Skin (Milwood, N.Y.) (13.11.2023)

Get full text

Journal Article

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

by ARMENGOL TUBAU, Clara, AGELL GIMENO, Helena, GARCIA GIL, Maria Esther, MAESO NAVAL, Silvia
Year of Publication 22.05.2024

Get full text

Patent

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

by ARMENGOL TUBAU, Clara, AGELL GIMENO, Helena, GARCIA GIL, Maria Esther, MAESO NAVAL, Silvia
Year of Publication 01.02.2024

Get full text

Patent

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

by ARMENGOL TUBAU, Clara, AGELL GIMENO, Helena, GARCIA GIL, Maria Esther, MAESO NAVAL, Silvia
Year of Publication 19.01.2023

Get full text

Patent

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

IL-13 ANTIBODIES FOR THE TREATMENT OF ATOPIC DERMATITIS

by MAESO NAVAL, SILVIA, ARMENGOL TUBAU, CLARA, GARCIA GIL, MARIA ESTHER, AGELL GIMENO, HELENA
Year of Publication 19.01.2023

Get full text

Patent

Il-13 antibodies for the treatment of atopic dermatitis

Il-13 antibodies for the treatment of atopic dermatitis

by MAESO NAVAL, SILVIA, ARMENGOL TUBAU, CLARA, GARCIA GIL, MARIA ESTHER, AGELL GIMENO, HELENA
Year of Publication 01.07.2024

Get full text

Patent